Stevanato Group S.p.A.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Franco Stevanato
- Full Time Employees
- 6,010
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- Via Molinella, 17 Piombino Dese PD Italy 35017
- IPO Date
- Jul 16, 2021
- CIK
- 0001849853
- Website
- stevanatogroup.com
- Similar Companies
- Business
- Stevanato Group S.p.A. (NYSE: STVN) provides integrated drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries; it operates through two segments, Biopharmaceutical and Diagnostic Solutions, and Engineering, delivering products, processes, and services across the drug life cycle from development to commercialization stages. The company manufactures advanced glass primary packaging under brands such as Ompi, including pre-fillable syringes, vials, cartridges, and ampoules; its EZ-fill pre-sterilized platform; drug delivery systems comprising pen injectors, auto-injectors, wearable injectors, and inhalers; in-vitro diagnostic consumables and medical components; visual inspection systems; assembly, packaging, and glass converting equipment; analytical testing services for container-drug interactions; and contract development and manufacturing for drug delivery devices. Founded in 1949 and headquartered in Piombino Dese, Italy, Stevanato Group maintains a global footprint with facilities across Europe, North America, South America, the Middle East, Africa, and Asia Pacific, including recent expansions such as a new manufacturing hub in Fishers, Indiana, USA, for drug containment and delivery production, and a €200 million financing package in 2025 to bolster capacity in Cisterna di Latina, Italy, and Fishers. In 2025, the company launched the ITC Syringe with Enlarged Inner Cone for enhanced intravenous drug delivery compatibility, expanded drug delivery systems capacity at its German facility to support scalable self-injection technologies, reported third-quarter revenue of €303.2 million reflecting robust growth, and formed the Alliance for RTU with SCHOTT Pharma and Gerresheimer to promote ready-to-use vials and cartridges among contract manufacturers. Stevanato Group, a subsidiary of Stevanato Holding S.R.L., serves pharmaceutical firms, biotech companies, diagnostics providers, and contract manufacturers focused on biologics, injectables, and mRNA therapies.
Company News
A Look at Stevanato Group SpA (STVN) After 3.4% Decline -- GF Value $25.98 vs Price $20.71
Stevanato Group: Alina Validates The Container-To-Device Flywheel
Stevanato Group SpA (STVN) Shares Fall 5.7% -- What GF Score of 87 Tells Investors
Stevanato Group Q2 Earnings Call Highlights
Stevanato Group Q2 Earnings Call Highlights
Is Stevanato (STVN) a Solid Growth Stock? 3 Reasons to Think "Yes"
Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript
Stevanato Group (STVN) Q2 Earnings Top Estimates
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside
2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now
Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting
Implied Volatility Surging for Stevanato Stock Options
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Stevanato Group S.p.A. (STVN) Q1 2026 Earnings Call Transcript
Stevanato Group (STVN) Q1 Earnings and Revenues Beat Estimates
Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026